Morgan Stanley Starts Exscientia PLC (EXAI) at Equalweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil, producer inflation weaken
- Oil falls on weaker demand outlook and higher US stocks
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
UPDATE: BofA Securities Starts Exscientia PLC (EXAI) at Buy on AI Enabled Drug Platform
October 26, 2021 6:07 AM EDT(Updated - October 27, 2021 7:27 AM EDT)
BofA Securities analyst Michael Ryskin initiates coverage on Exscientia PLC (NASDAQ: EXAI) with a Buy rating and a price target of $27.00.
The analyst stated "Exscientia is a tech-enabled drug discovery platform company, leveraging artificial... More
